INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory
View HTML
Toggle Summary NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 19, 2016-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 12, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 28, 2016-- NantKwest Inc. (Nasdaq:NK) today announced that Company management will present at the Piper Jaffray 28 th Annual Health Care Conference in New York, NY at 4:00 pm Eastern Time (ET) on Tuesday, November 29, 2016 .
View HTML
Toggle Summary Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential “Vaccine” Protective Effect to be Highlighted in Oral Presentation at the 58th Annual Meeting of the American Society of Hematology
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget
Next Generation NK Cell Therapy Poised to Transition into Human Clinical Trials CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using
View HTML
Toggle Summary NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
Promising Clinically Meaningful Responses Seen Including a Radiological Complete Response in Early Data Analysis Presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 14, 2016-- NantKwest Inc.
View HTML
Toggle Summary NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology
Presentation of Combination Therapy with a CS1.taNK and Daratumumab in Multiple Myeloma Presentation of Activated Natural Killer Cell Therapy (aNK) in Acute Myeloid Leukemia Presentation of Preclinical Data of a CD19.taNK Targeting Non-Hodgkin Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology
Presentation of Combination Therapy with a CS1.taNK and Daratumumab in Multiple Myeloma Presentation of Activated Natural Killer Cell Therapy (aNK) in Acute Myeloid Leukemia Presentation of Preclinical Data of a CD19.taNK Targeting Non-Hodgkin Lymphoma Culver City, November 3, 2016 NantKwest Inc.
View HTML
Toggle Summary Altor BioScience Corporation and NantKwest Inc. Announce Co-Development Agreement to Advance Innovative Natural Killer Cell Combination Immunotherapies for the Treatment of Cancer
Cancer moonshot 2020 milestone: novel-novel combination of GPS Cancer guided cell based NK cell therapy and fusion proteins in QUILT trial CULVER CITY, Calif. & MIRAMAR, Fla. --(BUSINESS WIRE)--Oct. 4, 2016-- Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based
View HTML